– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients – – CHS-114 ...

-Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical studies- -Data show CCR8 target is present with high prevalence and ...

CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells ...

STRASBOURG, France & MONTREAL & BOSTON--(BUSINESS WIRE)--Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in ...

SENTI-202, a chimeric antigen receptor natural (CAR) killer cell therapy, achieved complete remission in patients with acute myeloid leukemia, offering a faster alternative to conventional CAR T-cell ...

The MarketWatch News Department was not involved in the creation of this content. -- First patient dosed in France, expanding the DOMISOL study beyond Australia -- DT--7012 is being evaluated as ...

Domain Therapeutics and Chime Biologics signed a manufacturing service agreement for the production of Domain’s best-in-class Treg depleting anti-CCR8 antibody candidate, DT-7012. This phase of ...

Researchers from Takeda Pharmaceutical Co. Ltd. detailed the preclinical characterization of TAK-188, a first-in-class anti-CCR8 antibody-drug conjugate (ADC) designed to selectively target CCR8+ ...

In most solid tumors, high numbers of regulatory T (Treg) cells are associated with poorer outcomes because they dampen the immune system's ability to fight against a tumor. Colorectal cancer, however ...

First patient dosed in France, expanding the DOMISOL study beyond Australia DT‑7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development program ...